Eliquis vs Xarelto: Which Oral Anticoagulant Is Right for You?

How Eliquis and Xarelto Work

Both drugs block Factor Xa, the enzyme that converts prothrombin to thrombin, stopping the coagulation cascade before a clot can solidify. No conversion to an active metabolite is required. Onset of anticoagulation occurs within 1 to 4 hours of the first dose, which is one reason neither drug needs bridging with heparin for most indications.

Apixaban is approximately 50% renally cleared, with the rest eliminated hepatically. Rivaroxaban is about 33% renally eliminated as unchanged drug, and a further 33% is metabolized hepatically before renal excretion. The difference in renal clearance fractions matters enormously in chronic kidney disease, and this single pharmacokinetic distinction drives many prescribing decisions in nephrology-cardiology overlap cases. Bioavailability for apixaban is roughly 50% regardless of food. Rivaroxaban's 20 mg tablet, by contrast, requires food to reach 66% versus 80% bioavailability, which is why the evening-meal instruction on Xarelto is not optional and missing it reduces drug exposure meaningfully.

Half-life for apixaban is 8 to 15 hours; for rivaroxaban it is 5 to 9 hours in younger patients and up to 13 hours in the elderly. Both have half-lives short enough that holding two doses before an elective procedure substantially reduces anticoagulant effect, a practical advantage over warfarin that requires days of bridging management.

The Key Randomized Trials

ARISTOTLE: Apixaban vs Warfarin in AF

The ARISTOTLE trial (N=18,201) compared apixaban 5 mg twice daily against dose-adjusted warfarin in patients with non-valvular atrial fibrillation over a median 1.8 years. Apixaban reduced stroke or systemic embolism by 21% (1.27% vs 1.60% per year; hazard ratio 0.79, P<0.001 for non-inferiority, P=0.01 for superiority). Major bleeding fell by 31% (2.13% vs 3.09% per year; P<0.001), and intracranial hemorrhage dropped by 58%. All-cause mortality was 3.52% per year with apixaban versus 3.94% with warfarin, a statistically significant reduction [1].

ROCKET-AF: Rivaroxaban vs Warfarin in AF

ROCKET-AF (N=14,264) tested rivaroxaban 20 mg once daily against warfarin in a higher-risk AF population (mean CHA2DS2-VASc score approximately 3.5). Rivaroxaban was non-inferior for the primary endpoint of stroke or systemic embolism (1.7% vs 2.2% per year; P<0.001 for non-inferiority). Major bleeding rates were similar between groups (3.6% rivaroxaban vs 3.4% warfarin; P=0.58), though intracranial bleeding was lower with rivaroxaban (0.5% vs 0.7%; P=0.02). Fatal bleeding was also significantly lower with rivaroxaban [2].

EINSTEIN-DVT and EINSTEIN-PE: Rivaroxaban for VTE

The EINSTEIN program studied rivaroxaban for acute DVT and PE using a single-drug approach: 15 mg twice daily for 21 days, then 20 mg once daily. In EINSTEIN-DVT (N=3,449), rivaroxaban was non-inferior to enoxaparin plus warfarin for recurrent VTE (2.1% vs 3.0%; P<0.001 for non-inferiority) with significantly less major or clinically relevant non-major bleeding (8.1% vs 11.4%; P=0.003) [3].

AMPLIFY: Apixaban for VTE

AMPLIFY (N=5,395) tested apixaban 10 mg twice daily for 7 days then 5 mg twice daily for 6 months. The primary outcome of recurrent VTE or VTE-related death was 2.3% with apixaban versus 2.7% with conventional therapy, confirming non-inferiority. Major bleeding was strikingly lower: 0.6% with apixaban versus 1.8% with standard anticoagulation, a 69% relative reduction (P<0.001) [4].

Head-to-Head Observational Evidence

No large, prospective, randomized trial has directly compared apixaban versus rivaroxaban. ARISTOPHANES (Anticoagulants for Reduction In Stroke: Observational Pooled analysis on Health Outcomes and Experience of Patients), published in 2019, pooled data from 3 US insurance databases covering 234,766 patients with non-valvular AF over 12 months. Patients on apixaban had a lower risk of stroke or systemic embolism compared with rivaroxaban (HR 0.82 to 95% CI 0.75 to 0.90) and a significantly lower rate of major bleeding (HR 0.65 to 95% CI 0.60 to 0.70) [5]. A 2022 network meta-analysis in JAMA Network Open incorporating 23 trials and over 150,000 patients ranked apixaban highest for minimizing major bleeding across all approved DOACs [6].

These are observational findings. Residual confounding by indication, severity, and prescriber preference cannot be ruled out, but the direction and magnitude of the bleeding difference are consistent across multiple independent analyses.

Dosing and Administration Compared

Apixaban (Eliquis)

• AF stroke prevention: 5 mg twice daily. Reduce to 2.5 mg twice daily if two of three criteria are met: age 80 or older, weight 60 kg or less, serum creatinine 1.5 mg/dL or higher.
• DVT/PE treatment: 10 mg twice daily for 7 days, then 5 mg twice daily.
• DVT/PE extended prevention: 2.5 mg twice daily after at least 6 months of treatment.
• Post-surgical prophylaxis (hip or knee): 2.5 mg twice daily.

Rivaroxaban (Xarelto)

• AF stroke prevention: 20 mg once daily with evening meal (15 mg daily if CrCl 15 to 50 mL/min).
• DVT/PE treatment: 15 mg twice daily for 21 days, then 20 mg once daily with food.
• DVT/PE extended prevention: 10 mg once daily after at least 6 months.
• Post-surgical prophylaxis: 10 mg once daily.

The once-daily rivaroxaban schedule appeals to patients who struggle with twice-daily regimens. Adherence data do, however, indicate that twice-daily regimens achieve comparable real-world adherence when the medication is tied to a habitual activity like morning and evening meals. Each missed rivaroxaban dose removes a full day of anticoagulation coverage, whereas missing one apixaban dose leaves the second dose of the day still providing some protection.

Bleeding Risk: Where the Two Drugs Differ Most

Gastrointestinal bleeding is the safety signal that separates these agents in everyday clinical practice. The 2019 ARISTOPHANES analysis found rivaroxaban was associated with a GI bleeding rate of 1.4 per 100 patient-years versus 0.96 with apixaban, a meaningful absolute difference in a population already at elevated GI bleeding risk from age and comorbidities [5].

Intracranial hemorrhage rates are low and comparable between the two drugs in most analyses, approximately 0.4 to 0.6% annually, which is substantially better than warfarin's rate of 0.9 to 1.2%.

High-risk GI bleeding candidates, including those with a history of peptic ulcer disease, active NSAID use, or prior GI bleed, are generally better served by apixaban based on current evidence. The 2023 ACC/AHA/ACCP/HRS Atrial Fibrillation Guideline states: "In patients with AF at elevated risk of GI bleeding, apixaban may be preferred over rivaroxaban given lower observed rates of GI hemorrhage in comparative effectiveness studies" [7].

Renal Dosing and CKD Considerations

Renal function affects both drugs, but the thresholds and mechanisms differ.

For apixaban in AF, dose reduction to 2.5 mg twice daily is triggered by a two-out-of-three criteria (age, weight, creatinine) rather than by a specific CrCl cutoff alone, though the FDA label cautions against use in dialysis patients due to limited data. Several small trials and registry analyses suggest apixaban may be safer than warfarin even in ESRD, and the AXADIA pilot randomized 97 dialysis patients to apixaban versus warfarin, finding similar bleeding rates and reasonable drug exposure [8].

For rivaroxaban in AF, the label recommends 15 mg once daily when CrCl falls to 15 to 50 mL/min, and the drug should be avoided in AF when CrCl drops below 15 mL/min. This is because rivaroxaban's greater dependence on direct renal excretion of unchanged drug leads to accumulation at low GFR.

In CKD stages 3 and 4, apixaban is generally the preferred DOAC based on these pharmacokinetic differences and the data from ARISTOTLE's CKD subgroup showing preserved efficacy and lower bleeding versus warfarin.

Drug Interactions

Both apixaban and rivaroxaban are substrates of CYP3A4 and P-glycoprotein (P-gp). Strong inhibitors of both pathways, such as ketoconazole, itraconazole, lopinavir/ritonavir, and clarithromycin, can increase plasma concentrations of both drugs substantially, raising bleeding risk. Strong dual inducers of CYP3A4 and P-gp, including rifampin, carbamazepine, and phenytoin, reduce DOAC exposure and may leave patients inadequately anticoagulated.

Concomitant antiplatelet therapy with aspirin or P2Y12 inhibitors increases absolute bleeding risk with either drug. The AUGUSTUS trial (N=4,614) specifically examined apixaban versus vitamin K antagonists in AF patients on antiplatelet therapy following ACS or PCI. Apixaban plus a P2Y12 inhibitor (without aspirin) produced significantly less major or clinically relevant bleeding than warfarin-based regimens (10.5% vs 14.7%; P<0.001) [9].

NSAIDs taken regularly alongside either DOAC roughly double the absolute risk of GI bleeding. Patients who require chronic NSAID therapy should discuss the risk carefully with their clinician and consider gastroprotection with a proton pump inhibitor.

Reversal Agents

Andexanet alfa (Andexxa) is the specific reversal agent for both apixaban and rivaroxaban, approved by the FDA in 2018 for life-threatening or uncontrolled bleeding. In the ANNEXA-4 prospective cohort study (N=352), andexanet alfa achieved excellent or good hemostasis in 82% of patients within 12 hours, with anti-Xa activity reduced by 92% for apixaban and 97% for rivaroxaban [10].

For less severe bleeding or non-urgent reversal (such as prior to emergency surgery), 4-factor prothrombin complex concentrate (4F-PCC, e.g., Kcentra) at 25 to 50 units/kg is used off-label and is far less expensive than andexanet alfa. Activated charcoal within 2 hours of ingestion reduces GI absorption for both agents. Dialysis is not effective for removing either drug.

Idarucizumab (Praxbind) reverses dabigatran only and has no effect on apixaban or rivaroxaban.

Cost and Access

Brand-name Eliquis and brand-name Xarelto both carry list prices over $500 per month without insurance in the US. Generic rivaroxaban received FDA approval in January 2023 and is now available from multiple manufacturers, with GoodRx prices as low as $30 to $60 per month depending on pharmacy and dose. Generic apixaban is not expected until 2028 under current patent agreements, making rivaroxaban the substantially cheaper option for uninsured or underinsured patients in the near term.

Both manufacturers offer patient assistance programs. Bristol-Myers Squibb/Pfizer's Eliquis Together copay card can reduce out-of-pocket costs to $10 per month for eligible commercially insured patients. Janssen's Xarelto patient assistance program provides similar support.

Eliquis vs Xarelto in Context: Other Cardiometabolic Drug Comparisons

The apixaban-versus-rivaroxaban decision is one of several drug-class comparisons cardiometabolic patients and their clinicians routinely face.

ApoB vs LDL as cardiovascular risk markers. LDL-cholesterol measures the cholesterol mass in low-density lipoprotein particles. ApoB measures the actual number of atherogenic particles, because each VLDL, IDL, LDL, and Lp(a) particle carries exactly one ApoB molecule. A patient with small, dense LDL particles can have a normal LDL-C and an elevated ApoB, a pattern that carries higher cardiovascular risk. The 2022 ACC Expert Consensus Decision Pathway identified ApoB as a preferred alternative to LDL-C when non-HDL cholesterol and LDL-C are discordant, and recommended a target of <65 mg/dL ApoB for very high-risk patients [11].

Statin vs bempedoic acid. High-intensity statins remain first-line for LDL and ApoB reduction. Bempedoic acid (Nexletol), an ATP-citrate lyase inhibitor, reduces LDL-C by approximately 18% as monotherapy and is a statin-alternative for patients who cannot tolerate myalgias. CLEAR Outcomes (N=13,970) showed bempedoic acid reduced the composite of cardiovascular death, MI, stroke, and coronary revascularization by 13% versus placebo over a median 40.6 months in statin-intolerant patients [12]. Statins typically achieve 40 to 60% LDL reduction at high intensity, a magnitude bempedoic acid does not match, but for the statin-intolerant population it represents a proven option.

Lisinopril vs losartan. Both drugs reduce cardiovascular events in hypertension, heart failure, and diabetic nephropathy, but through different mechanisms. Lisinopril is an ACE inhibitor that blocks the conversion of angiotensin I to angiotensin II and raises bradykinin. Losartan is an ARB that blocks the AT1 receptor. ACE inhibitor cough, caused by bradykinin accumulation, affects 5 to 20% of patients and is substantially rarer with ARBs. The ONTARGET trial (N=25,620) showed losartan was non-inferior to ramipril (another ACE inhibitor) for the primary composite of cardiovascular death, MI, and stroke, with a lower rate of cough [13].

Metoprolol vs carvedilol. Metoprolol succinate (Toprol-XL) is a selective beta-1 blocker. Carvedilol blocks beta-1, beta-2, and alpha-1 receptors, providing vasodilation in addition to rate and contractility control. In heart failure with reduced ejection fraction, COPERNICUS (N=2,289) demonstrated carvedilol reduced all-cause mortality by 35% versus placebo in severe systolic heart failure, and carvedilol is generally preferred over metoprolol in HFrEF when vasodilation is desirable [14]. In patients with reactive airway disease, metoprolol's relative beta-1 selectivity makes it the safer choice.

Which Patients Should Consider Each Drug

Apixaban is generally preferred when:

• The patient has a prior GI bleed or active GI pathology.
• CrCl is between 15 and 30 mL/min (most clinicians choose apixaban in this range).
• The patient is also taking a single antiplatelet agent post-ACS.
• Cost is covered by insurance or the patient qualifies for manufacturer assistance.

Rivaroxaban may be more appropriate when:

• Strict once-daily dosing adherence is essential and twice-daily is genuinely not feasible.
• The patient needs a lower-cost generic option and has no elevated GI bleeding risk factors.
• CrCl is above 50 mL/min and no GI risk factors exist.
• The prescriber is managing VTE and prefers the well-validated EINSTEIN single-drug regimen.

The 2023 ACC/AHA/ACCP/HRS AF Guideline offers this language on DOAC selection: "The choice between apixaban and rivaroxaban should be individualized, considering patient-specific factors including bleeding risk, renal function, adherence, and cost access, as no large-scale randomized trial has directly compared these two agents" [7].